Core Viewpoint - INVO Fertility, Inc. has announced a strategic separation of its fertility and oncology operations to maximize shareholder value, returning to a focus on the fertility marketplace and the distribution of its FDA-cleared INVOcell device [1][4][5]. Group 1: Company Name Change and Structure - The company has been renamed to "INVO Fertility, Inc." effective April 14, 2025, with a new Nasdaq ticker symbol "IVF" to be implemented shortly [2]. - The separation will allow INVO Fertility to concentrate on establishing, acquiring, and operating fertility clinics, as well as distributing the INVOcell device [3][4]. Group 2: Business Focus and Strategy - INVO Fertility aims to leverage its existing operations in Wisconsin, Alabama, and Georgia to expand its network of fertility centers across the U.S., capitalizing on a growing market opportunity [5]. - The company plans to divest a majority stake in its subsidiary, NAYA Therapeutics, while retaining a minority position to benefit from potential value appreciation in its bifunctional antibodies [4][5]. Group 3: NAYA Therapeutics Overview - NAYA Therapeutics will operate as a private company focused on the clinical development of bifunctional antibodies, with several promising candidates in its pipeline targeting oncology [7]. - The company’s lead candidate, NY-303, is set to enter a Phase I/IIa trial in H2 2025, targeting a significant portion of the current treatable market for hepatocellular carcinoma (HCC) [7].
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”